期刊
PHARMACEUTICS
卷 12, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics12060501
关键词
antimicrobial peptides; cationic amphipathic peptides; host defense peptides; gene-encoded antimicrobial peptides; helical antimicrobial peptides; polymyxins; colistin; synergy; antibiotic resistance; multidrug-resistant bacteria; ESKAPE pathogens; antibiotics; peptide antibiotics
资金
- NIH [GM125917, AI133351]
The increasing rate of antibiotic resistance constitutes a global health crisis. Antimicrobial peptides (AMPs) have the property to selectively kill bacteria regardless of resistance to traditional antibiotics. However, several challenges (e.g., reduced activity in the presence of serum and lack of efficacy in vivo) to clinical development need to be overcome. In the last two decades, we have addressed many of those challenges by engineering cationic AMPsde novofor optimization under test conditions that typically inhibit the activities of natural AMPs, including systemic efficacy. We reviewed some of the most promising data of the last two decades in the context of the advancement of the field of helical AMPs toward clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据